• Today is: Sunday, May 22, 2022

Study on Promising Parkinson’s Disease Drug Supports Fast Track to Clinical Trials

paricksons disease
Dr. Ranjini
Dr. Ranjini
August28/ 2015

Parkinson’s disease (PD) is characterized by degeneration of central nervous system and affects almost 10 million people across the world. Even though India has the lowest incidence overall-70 in 100,000, the highest incidence of PD is found in the Parsi community in Mumbai where it affects almost 328 people out of 100,000. Incidence of PD increases with age and men are 1.5 times more likely to have Parkinson’s as compared to women.

In view of these numbers, recent research has shed light on a potential new drug for Parkinson’s disease. Researchers at the Sheffield Institute of Translational Neuroscience (SITraN), in collaboration with scientists from the University of York found that UDCA (ursodeoxycholic acid) a drug that has been in use for liver disease has the potential to slow down Parkinson’s disease.

Dr Heather Mortiboys, senior researcher at the University of Sheffield explained that the drug UDCA improved the mitochondrial function as shown by the increase of oxygen consumption and cellular energy levels in the tissue of LRRK2 carriers with PD. LRRK2 gene mutation is the most common cause for PD.

Oliver Bandmann, Professor of Movement Disorders Neurology at the University of Sheffield and Honorary Consultant Neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, further added that the drug may benefit other neurodegenerative diseases as well. Dr.Arthur, Director of Research and Development at Parkinson’s UK who has also partly funded the study talked about the need for new treatments that can slow or stop PD and the hope this drug brings in cutting costs and time once it fast tracks to clinical trials. This study was published in the journal Neurology and funding was also received from the Wellcome Trust and the Norwegian Parkinson Foundation.

The combined costs (direct + indirect) of Parkinson’s is estimated to be around $25 billion in United States itself. And this drug can potentially cut costs tremendously once it is approved for use in Parkinson’s disease.

Dr. Ranjini
Dr. Ranjini

Dr.Ranjini is a Bangalore based health professional and MBA holder. She currently works as consultant for Xpedient Digital Media in the areas of market research, business development and healthcare marketing. Her experience includes working with pharmaceutical and media companies in India and USA.

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

2 × 1 =